Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis

• Verfasst von: Witzel, Simon [VerfasserIn]
• Verfasst von: Frauhammer, Felix [VerfasserIn]
• Verfasst von: Steinacker, Petra [VerfasserIn]
• Verfasst von: Devos, David [VerfasserIn]
• Verfasst von: Pradat, Pierre-Francois [VerfasserIn]
• Verfasst von: Meininger, Vincent [VerfasserIn]
• Verfasst von: Halbgebauer, Steffen [VerfasserIn]
• Verfasst von: Oeckl, Patrick [VerfasserIn]
• Verfasst von: Schuster, Joachim [VerfasserIn]
• Verfasst von: Anders, Simon [VerfasserIn]
• Verfasst von: Dorst, Johannes [VerfasserIn]
• Verfasst von: Otto, Markus [VerfasserIn]
• Verfasst von: Ludolph, Albert C. [VerfasserIn]
• Titel: Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis
• Titelzusatz: development and validation of a prediction model to improve interventional trials
• Verf.angabe: Simon Witzel, Felix Frauhammer, Petra Steinacker, David Devos, Pierre-Francois Pradat, Vincent Meininger, Steffen Halbgebauer, Patrick Oeckl, Joachim Schuster, Simon Anders, Johannes Dorst, Markus Otto and Albert C. Ludolph
• E-Jahr: 2021
• Jahr: 26 August 2021
• Umfang: 12 S.
• Fussnoten: Gesehen am 20.01.2022
• Titel Quelle: Enthalten in: Translational neurodegeneration
• Ort Quelle: London : Biomed Central, 2012
• Jahr Quelle: 2021
• Band/Heft Quelle: 10(2021), 1, Artikel-ID 31, Seite 1-12
• ISSN Quelle: 2047-9158
• DOI: doi:10.1186/s40035-021-00257-y
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: alsfrs-r
• Sach-SW: Amyotrophic lateral sclerosis
• Sach-SW: chain
• Sach-SW: clinical-trials
• Sach-SW: dexpramipexole
• Sach-SW: diagnosis
• Sach-SW: Disease progression
• Sach-SW: double-blind
• Sach-SW: Interventional trials
• Sach-SW: lithium
• Sach-SW: Neurofilament light
• Sach-SW: placebo
• Sach-SW: Prediction model
• Sach-SW: Statistical power
• Sach-SW: survival
• K10plus-PPN: 1786596008

Abstract

Background Interventional trials in amyotrophic lateral sclerosis (ALS) suffer from the heterogeneity of the disease as it considerably reduces statistical power. We asked if blood neurofilament light chains (NfL) could be used to anticipate disease progression and increase trial power. Methods In 125 patients with ALS from three independent prospective studies-one observational study and two interventional trials-we developed and externally validated a multivariate linear model for predicting disease progression, measured by the monthly decrease of the ALS Functional Rating Scale Revised (ALSFRS-R) score. We trained the prediction model in the observational study and tested the predictive value of the following parameters assessed at diagnosis: NfL levels, sex, age, site of onset, body mass index, disease duration, ALSFRS-R score, and monthly ALSFRS-R score decrease since disease onset. We then applied the resulting model in the other two study cohorts to assess the actual utility for interventional trials. We analyzed the impact on trial power in mixed-effects models and compared the performance of the NfL model with two currently used predictive approaches, which anticipate disease progression using the ALSFRS-R decrease during a three-month observational period (lead-in) or since disease onset (Delta FRS). Results Among the parameters provided, the NfL levels (P < 0.001) and the interaction with site of onset (P < 0.01) contributed significantly to the prediction, forming a robust NfL prediction model (R = 0.67). Model application in the trial cohorts confirmed its applicability and revealed superiority over lead-in and Delta FRS-based approaches. The NfL model improved statistical power by 61% and 22% (95% confidence intervals: 54%-66%, 7%-29%). Conclusion The use of the NfL-based prediction model to compensate for clinical heterogeneity in ALS could significantly increase the trial power. NCT00868166, registered March 23, 2009; NCT02306590, registered December 2, 2014.